In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bristol-Myers Squibb acquires Celgene for $74bn, deepening strength in oncology

Executive Summary

In the fourth-largest biopharma acquisition to date, Bristol-Myers Squibb Co. bought top-tier public biotech Celgene Corp. for $74bn. For each Celgene share, BMS will issue one of its shares (valued at $50 each) and pay $50 in cash, equating to a per-share price of $100, or a 58% premium. Celgene also gets one tradeable contingent value right (CVR) for each of its shares, providing additional payments of $9 in cash based on regulatory milestones. At closing, BMS stockholders will own 69% of the combined entity, and Celgene shareholders the rest.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash for Equity
    • Payment Includes Stock

Related Companies